Main description:

Neurobiology and Physiology of the Endocannabinoid System offers readers a comprehensive reference on the neurobiology of this system and the use of cannabimimetic compounds to induce neurological changes and confer symptom relief. With sections on both natural and synthetic compounds, the book's broad coverage allows readers to learn about their use with multiple conditions, as well as the working biology of the endocannabinoid system, its receptors and its ligands. This volume provides a platform for research on the effects of this system and its modulation in brain function and neurological dysfunction.

Contents:

I. Setting the scene and introductory chapters 1. Distribution of the endocannabinoid system: Linking signalling and development 2. The endocannabinoid system, immunomodulation, and LPS-induced inflammation 3. Physiology of the endocannabinoid systems: Imaging and the use of positron emission tomography (PET) 4. The endocannabinoid system and aging 5. The endocannabinoid system and post traumatic stress disorder (PTSD): A new narrative

II. Neurobiology of the endocannabinoid system 6. The protective effect of the endocannabinoid system in neurotoxin induced damage to hippocampal neurons: A focus on light and electron microscopy 7. Endocannabinoid Signaling and excitatory and inhibitory synapses 8. The endocannabinoids and potassium channels: An updated narrative 9. Social interactions and neural activity: Linking cellular studies and endocannabinoid signalling 10. Exercise and Parkinson's disease: Linking in the cannabinoid type 1 (CB1) and type 2 (CB2), and mu-opioid receptors 11. Endocannabinoids and inhalant misuse: Neuropsychological aspects 12. Fatty acid amide hydrolase (FAAH) in substance use disorders: FAAH regulation and inhibition in cannabis, alcohol, nicotine, stimulant, and opioid use disorders 13. Treatment of pain with dual fatty acid amide hydrolase (FAAH) enzyme and human soluble epoxide hydrolase (sEH) enzyme inhibitors: Interlinking the endocannabinoid system 14. WWL70: linking the hydrolyses 2-arachidonoylglycerol, endocannabinoid and eicosanoid pathways: Therapeutic potential and neurological disease 15. Endocannabinoid catabolic enzyme inhibitors and pain alleviation 16. The endocannabinoid system in health and disease: Features in epilepsy 17. The endocannabinoid system and autoimmune demyelination: A focus on multiple sclerosis 18. Endocannabinoid signaling and the lateral habenula 19. On the interplay among endocannabinoid, noradrenergic and glucocorticoid systems: Evidence from aversive memory studies

III. Receptor biology and responses 20. Adenosine A2A-cannabinoid CB1 receptor heteromers in the brain: From trans-inhibition to trans-activation 21. Hippocampal CB1, CB2 receptors, the endocannabinoid system and fear memory 22. Beta-caryophyllene, the CB2 cannabinoid receptor-specific agonists and wound healing 23. The nigrostriatal dopaminergic pathway: Impact of WIN 55212-2 as a potent cannaboinoid receptor agonist 24. Peripheral cannabinoid receptor 1 antagonists and impact on adipocytes 25. Endocannabinoid system receptors in plasma membranes: Extraction, lipid rafts and the cortex 26. Applications to wound healing: Cannabinoid receptor 1 antagonism and collagen deposition 27. Role of the Transient Receptor Potential Vanilloid 1 (TRPV1), a component of the endocannabinoid system, in anxiety, depression, and cocaine addiction 28. Allosteric modulators of the endocannabinoid system: Org27569 and cannabinoid receptor 1 (CB1) 29. Naturally occurring DELTA-9-tetrahydrocannabinol-derivatives and binding to CB1 and CB2 receptors: Linking in the endocannabinoid system

IV. Profiles and behaviour of selective endocannabinoids 30. New cannabinoid receptor type 1 and 2 agonists and applications to understanding the endocannabinoid system 31. Fatty acid amide hydrolase, the endocannabinoid anandamide and neurological disease 32. The endocannabinoid-system in the immuno-biology of dendritic cells 33. Palmitoylethanolamide and other anandamide congeners in neuroinflammation-based disorders: linking in the endocannabinoid system 34. Endocannabinoid modulation of synaptic function and behavior in the dorsomedial hypothalamus 35. Key role of anandamide and the endocannabinoid system in the modulation of cardio-renal homeostasis 36. The endocannabinoid system: Signaling and social motivation

V. Exogenous, synthetic other compounds linking in the endocannabinoid system 37. Safety and toxicology of the dietary cannabinoid beta-caryophyllene 38. Synthetic cannabimimetics: An overview

VI. Compartive studies in non neurological systems 39. Non Neurological Aspects of the Endocannabinoid System: Non Alcoholic Fatty Liver Disease 40. Components of the Endocannabinoid system: Hepatic expression levels of the cannabinoid receptors and microRNAs 41. Tumour growth and the endocannabinoid system: Investigating CB2 agonists 42. Linking Endocannabinoid System, Palmitoylethanolamide and Sarcopenia in view of therapeutic outcomes

VII. Resources 43. Endocannabinoids and Resources